ClinVar. 2016. http://www.ncbi.nlm.nih.gov/clinvar/. Accessed 28 June 2016.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. doi:10.1038/gim.2015.30.
Article
PubMed
PubMed Central
Google Scholar
Norton N, Robertson PD, Rieder MJ, Zuchner S, Rampersaud E, Martin E, et al. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet. 2012;5(2):167–74. doi:10.1161/CIRCGENETICS.111.961805.
Article
PubMed
PubMed Central
Google Scholar
Shearer AE, Eppsteiner RW, Booth KT, Ephraim SS, Gurrola 2nd J, Simpson A, et al. Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants. Am J Hum Genet. 2014;95(4):445–53. doi:10.1016/j.ajhg.2014.09.001.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91. doi:10.1038/nature19057.
Song W, Gardner SA, Hovhannisyan H, Natalizio A, Weymouth KS, Chen W, et al. Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification. Genet Med. 2016;18(8):850–4. doi:10.1038/gim.2015.180.
Article
CAS
PubMed
Google Scholar
Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2016. [Epub ahead of print]. doi:10.1038/gim.2016.90.
Paludan-Müller C, Ahlberg G, Ghouse J, Herfelt C, Svendsen JH, Haunsø S, et al. Integration of 60,000 exomes and ACMG guidelines question the role of Catecholaminergic Polymorphic Ventricular Tachycardia-associated variants. Clin Genetics. 2017;91(1):63–72. doi:10.1111/cge.12847.
Article
Google Scholar
ExAC. ExAC.r0.3.sites.vep.vcf.gz. ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/. Accessed 9 Feb 2016.
Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16(11):665–77. doi:10.1038/nrm4063.
Article
CAS
PubMed
Google Scholar
Stenson PD, Mort M, Ball EV, Shaw K, Phillips AD, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2014;133(1):1–9. doi:10.1007/s00439-013-1358-4.
Article
CAS
PubMed
Google Scholar
ClinVar. ClinVarFullRelease_2016-01.xml.gz. ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/xml/. Accessed 9 Feb 2016.
Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, et al. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am J Hum Genet. 2013;93(4):631–40. doi:10.1016/j.ajhg.2013.08.006.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ghouse J, Have CT, Weeke P, Bille Nielsen J, Ahlberg G, Balslev-Harder M, et al. Rare genetic variants previously associated with congenital forms of long QT syndrome have little or no effect on the QT interval. Eur Heart J. 2015;36(37):2523.
Article
PubMed
Google Scholar
Ghouse J, Have CT, Skov MW, Andreasen L, Ahlberg G, Nielsen JB et al. Numerous Brugada syndrome-associated genetic variants have no effect on J-point elevation, syncope susceptibility, malignant cardiac arrhythmia, and all-cause mortality. Genet Med. 2016. [Epub ahead of print]. doi:10.1038/gim.2016.151.
Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 1994;8(4):399–404. doi:10.1038/ng1294-399.
Article
CAS
PubMed
Google Scholar
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–92.
Article
CAS
PubMed
Google Scholar
Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. 2015;17(5):533–44. doi:10.1016/j.jmoldx.2015.04.009.
Article
PubMed
Google Scholar
Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomark Prev. 2004;13(12):2078–83.
CAS
Google Scholar
Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. Genetic/familial high-risk assessment: breast and ovarian, Version 2.2015. J Natl Compr Cancer Netw. 2016;14(2):153–62.
Google Scholar
Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937–48. doi:10.1016/j.ajhg.2008.02.008.
Article
CAS
PubMed
PubMed Central
Google Scholar
Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A. 2001;98(6):3232–6. doi:10.1073/pnas.051624098.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang MQ. Statistical features of human exons and their flanking regions. Hum Mol Genet. 1998;7(5):919–32.
Article
CAS
PubMed
Google Scholar
Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997;60(5):1059–67.
CAS
PubMed
PubMed Central
Google Scholar
Millot G, Carvalho MA, Caputo SM, Vreeswijk MPG, Brown MA, Webb M, et al. A guide for functional analysis of BRCA1 variants of uncertain significance (VUS). Hum Mutat. 2012;33(11):1526–37. doi:10.1002/humu.22150.
Article
CAS
PubMed
PubMed Central
Google Scholar
Le Calvez-Kelm F, Lesueur F, Damiola F, Vallée M, Voegele C, Babikyan D, et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res. 2011;13(1):R6-R. doi:10.1186/bcr2810.
Article
Google Scholar
Miyaki M, Iijima T, Yamaguchi T, Hishima T, Tamura K, Utsunomiya J, et al. Germline mutations of the MYH gene in Japanese patients with multiple colorectal adenomas. Mutat Res. 2005;578(1–2):430–3. http://dx.doi.org/10.1016/j.mrfmmm.2005.01.017.
Article
CAS
PubMed
Google Scholar
Jordan DM, Kiezun A, Baxter SM, Agarwala V, Green RC, Murray MF, et al. Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. Am J Hum Genet. 2011;88(2):183–92. doi:10.1016/j.ajhg.2011.01.011.
Article
CAS
PubMed
PubMed Central
Google Scholar
Saltzman AJ, Mancini-DiNardo D, Li C, Chung WK, Ho CY, Hurst S, et al. The cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. Circ Res. 2010;106(9):1549–52. doi:10.1161/CIRCRESAHA.109.216291.
Article
CAS
PubMed
PubMed Central
Google Scholar
Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004;6(5):387–91. doi:10.1097/01.GIM.0000139506.11694.7C.
Article
PubMed
PubMed Central
Google Scholar
Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160–7. doi:10.1038/ng.2745.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tabor Holly K, Auer Paul L, Jamal Seema M, Chong Jessica X, Yu J-H, Gordon Adam S, et al. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. Am J Hum Genet. 2014;95(2):183–93. doi:10.1016/j.ajhg.2014.07.006.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gao F, Keinan A. High burden of private mutations due to explosive human population growth and purifying selection. BMC Genomics. 2014;15(4):1–7. doi:10.1186/1471-2164-15-S4-S3.
CAS
Google Scholar
Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA, Szolovits P, et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med. 2016;375(7):655–65. doi:10.1056/NEJMsa1507092.
Article
PubMed
Google Scholar
Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic Intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 2013;9(8):e1003709. doi:10.1371/journal.pgen.1003709.
Article
CAS
PubMed
PubMed Central
Google Scholar
Uglanitsa N, Oszurek O, Uglanitsa K, Savonievich E, Lubiński J, Cybulski C, et al. The contribution of founder mutations in BRCA1 to breast cancer in Belarus. Clin Genet. 2010;78(4):377–80. doi:10.1111/j.1399-0004.2010.01439.x.
Article
CAS
PubMed
Google Scholar
Janavičius R, Rudaitis V, Feng B-J, Ozolina S, Griškevičius L, Goldgar D, et al. Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation. Eur J Med Genet. 2013;56(3):125–30. http://dx.doi.org/10.1016/j.ejmg.2012.12.007.
Article
PubMed
Google Scholar
Blay P, Santamaría I, Pitiot AS, Luque M, Alvarado MG, Lastra A, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13:243. doi:10.1186/1471-2407-13-243.
Article
CAS
PubMed
PubMed Central
Google Scholar
Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1(3):397–412. doi:10.1007/s13167-010-0037-y.
Article
PubMed
PubMed Central
Google Scholar
Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. 2014;207(5):195–205. http://dx.doi.org/10.1016/j.cancergen.2014.05.002.
Article
PubMed
Google Scholar
Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hereditary Cancer Clin Pract. 2016;14:5. doi:10.1186/s13053-016-0046-5.
Article
CAS
Google Scholar
Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int. 2013;2013:928562. doi:10.1155/2013/928562.
Article
PubMed
PubMed Central
Google Scholar
Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker J-P, et al. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Res. 2012;14(4):R99-R. doi:10.1186/bcr3218.
Article
Google Scholar
Tea M-KM, Kroiss R, Muhr D, Fuerhauser-Rappaport C, Oefner P, Wagner TM, et al. Central European BRCA2 mutation carriers: Birth cohort status correlates with onset of breast cancer. Maturitas. 2014;77(1):68–72. http://dx.doi.org/10.1016/j.maturitas.2013.09.012.
Article
PubMed
Google Scholar
Kwong A, Shin VY, Ho JCW, Kang E, Nakamura S, Teo S-H, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet. 2016;53(1):15–23.
Article
CAS
PubMed
Google Scholar
Miramar MD, Calvo MT, Rodriguez A, Antón A, Lorente F, Barrio E, et al. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Res Treat. 2008;112(2):353–8. doi:10.1007/s10549-007-9868-1.
Article
CAS
PubMed
Google Scholar
Kim YC, Zhao L, Zhang H, Huang Y, Cui J, Xiao F et al. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients. Oncotarget. 2016;7(8):9600-12. doi:10.18632/oncotarget.7144.
Borg Å, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: The WECARE Study. Hum Mutat. 2010;31(3):E1200–40. doi:10.1002/humu.21202.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kluska A, Balabas A, Paziewska A, Kulecka M, Nowakowska D, Mikula M, et al. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genet. 2015;8:19. doi:10.1186/s12920-015-0092-2.
Google Scholar